A gene-therapy-based approach reports that an adenovirus-based cassette was able to carry and deliver the culprit missing gene for hemophilia A: factor VIII.Medscape Medical News

Related Links:

Abstract
Hemophilia is a congenital hemorrhagic disease caused by genetic abnormalities in coagulation factor VIII or factor IX. Current conventional therapy to prevent bleeding requires frequent intravenous injections of coagulation factor concentrates from early childhood. Accordingly, gene therapy for hemophilia remains an exciting future prospect for patients and their families, due to its potential to cure the disease through a one-time treatment. After a series of successes in basic research, recent clinical trials have demonstrated clear efficacy of gene therapy for hemophilia using adeno-associated virus (…

Gene therapy for hemophilia B aims to ameliorate bleeding risk and provide endogenous factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for FIX concentrate. AMT-060 combines an adeno-associated virus-5 (AAV5) vector with a liver-specific promoter driving expression of a codon-optimized wild-type human FIX gene. This multinational, open-label study included 10 adults with hemophilia B (FIX ≤2% of normal) and severe-bleeding phenotype. No participants tested positive for AAV5-neutralizing antibodies using a green-fluorescent protein-based assay, and all 10 were enrolled. A single d…

Source: BloodCategory: Hematology Authors: Tags: Free Research Articles, Thrombosis and Hemostasis, Clinical Trials and Observations, Gene Therapy Source Type: research

CONCLUSION: Achieving a safe and efficient remedy for hemophilia A and B by means of GT vector engineering needs further improvement. No randomized or quasi-randomized clinical trials of GT for hemophilia have been found. Given it is in its incipient period, there is need for well-designed clinical trials to evaluate the long-term practicability, efficacy and risks of GT for PWH.
PMID: 29446741 [PubMed – as supplied by publisher]

Source: Current Gene TherapyCategory: Genetics & Stem Cells Authors: Tags: Curr Gene Ther Source Type: research

Nuclease-Mediated Gene Therapies for Inherited Metabolic Diseases of the Liver

.
Yale J Biol Med. 2017 Dec;90(4):553-566
Authors: Bryson TE, Anglin CM, Bridges PH, Cottle RN
Abstract
Inherited metabolic diseases (IMDs) of the liver represent a vast and diverse group of rare genetic diseases characterized by the loss or dysfunction of enzymes or proteins essential for metabolic pathways in the liver. Conventional gene therapy involving adeno-associated virus (AAV) serotype 8 vectors provide therapeutically high levels of hepatic transgene expression facilitating the correction of the disease phenot…

Authors: George LA
Abstract
Concurrent with the development of recombinant factor replacement products, the characterization of the F9 and F8 genes over 3 decades ago allowed for the development of recombinant factor products and made the hemophilias a target disease for gene transfer. The progress of hemophilia gene therapy has been announced in 3 American Society of Hematology scientific plenary sessions, including the first “cure” in a large animal model of hemophilia B in 1998, first in human sustained vector-derived factor IX activity in 2011, and our clinical trial results reporting sustained vector…

Human Gene Therapy , Vol. 0, No. 0.

Source: Human Gene TherapyCategory: Genetics & Stem Cells Authors: Source Type: research

AbstractOver the last decade, pioneering liver-directed gene therapy trials for haemophilia B have achieved sustained clinical improvement after a single systemic injection of adeno-associated virus (AAV) derived vectors encoding the human factor IX cDNA. These trials demonstrate the potential of AAV technology to provide long-lasting clinical benefit in the treatment of monogenic liver disorders. Indeed, with more than ten ongoing or planned clinical trials for haemophilia A and B and dozens of trials planned for other inherited genetic/metabolic liver diseases, clinical translation is expanding rapidly. Gene therapy is l…

Human Gene Therapy , Vol. 0, No. 0.

Source: Human Gene TherapyCategory: Genetics & Stem Cells Source Type: research

(Mary Ann Liebert, Inc./Genetic Engineering News) A new study examined 42 combinations of promoters and enhancers for human factor VIII (hFVIII) gene expression to identify the optimal adeno-associated virus (AAV)-based gene therapy delivery vector constructs to take forward into development.

Katherine A. High, MD of Spark Therapeutics, presents a press briefing on Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Mean Factor IX Activity Levels of …


Author: ASHReport
Added: 12/07/2016

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image